Cerus Corporation to Participate in Upcoming Investor Conferences
August 28 2019 - 8:30AM
Business Wire
Cerus Corporation (Nasdaq: CERS) today announced that the
Company will participate in two upcoming investor conferences.
- William ‘Obi’ Greenman, Cerus’ president and chief executive
officer, is scheduled to present at the Baird 2019 Global
Healthcare Conference on Wednesday, September 4, 2019, at 12:15
p.m. EDT. The conference will be held at the InterContinental New
York Barclay in New York City.
- William ‘Obi’ Greenman and Kevin D. Green, Cerus’ vice
president finance and chief financial officer, are scheduled to
present at 17th Annual Morgan Stanley Healthcare Conference on
Monday, September 9, 2019, at 1:05 p.m. EDT. The conference will be
held at the Grand Hyatt New York in New York City.
Live webcasts of the presentations will be available on the
Investor Relations page of the Cerus web site at
http://www.cerus.com/ir. Replays of the presentations will be
available for approximately two weeks following the completion of
the events.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Based in Concord, California, our employees are
dedicated to deploying and supplying vital technologies and
pathogen-protected blood components for blood centers, hospitals
and ultimately patients who rely on safe blood. With the INTERCEPT
Blood System, we are focused on protecting patients by delivering
the full complement of reliable products and expertise for
transfusion medicine. Cerus develops and markets the INTERCEPT
Blood System, and remains the only company in the blood transfusion
space to earn both CE Mark and FDA approval for pathogen reduction
of both platelet and plasma components. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. The INTERCEPT Red
Blood Cell system is in clinical development. For more information
about Cerus, visit www.cerus.com.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190828005185/en/
Tim Lee – Investor Relations Director Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2023 to Apr 2024